Compare HIO & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIO | STRO |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.7M | 381.1M |
| IPO Year | N/A | N/A |
| Metric | HIO | STRO |
|---|---|---|
| Price | $3.56 | $25.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 379.4K | 271.5K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $0.72 |
| 52 Week High | $4.05 | $43.85 |
| Indicator | HIO | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 47.06 |
| Support Level | N/A | $23.53 |
| Resistance Level | $3.69 | $27.96 |
| Average True Range (ATR) | 0.04 | 1.46 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 41.67 | 76.89 |
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.